Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: Atezolizumab, Placebo, Doxorubicin, Cyclophosphamide, Paclitaxel, Trastuzumab, Pertuzumab, Trastuzumab Emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Kansas City, Missouri • New York, New York • Nashville, Tennessee

Conditions: Breast Cancer, Non-Hodgkin's Lymphoma
Interventions: Mesna, Saline, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: Mara Chambers; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 136
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Burbank, California + 104 more

Conditions: Triple Negative Breast Cancer
Interventions: Cyclophosphamide, Placebo, Doxorubicin, Paclitaxel, Carboplatin, Veliparib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 634 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 61
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 47 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions: AMG386 plus PLD, Placebo plus PLD; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 21
States / cities: Los Angeles, California • San Francisco, California • Norwalk, Connecticut + 18 more

Conditions: Platinum-Sensitive Ovarian Cancer in First Relapse
Interventions: Farletuzumab, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 35
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 32 more

Conditions: Carcinoma, Hepatocellular
Interventions: Sorafenib (Nexavar, BAY43-9006), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 18
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 14 more

Conditions: Lymphoma, Large B-Cell, Diffuse
Interventions: lenalidomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, prednisone, vincristine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 22
States / cities: Fayetteville, Arkansas • Orange, California • Sacramento, California + 16 more

Conditions: Sarcoma, Oral Mucositis
Interventions: Palifermin, Placebo, Adriamycin (Doxorubicin), Ifosfamide, Vincristine, Cisplatin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Soft Tissue Sarcoma
Interventions: doxorubicin in combination with palifosfamide-tris, doxorubicin in combination with placebo; Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 65 more

Conditions: Soft Tissue Sarcoma
Interventions: Olaratumab, Doxorubicin, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 30
States / cities: Duarte, California • Los Angeles, California • Stanford, California + 20 more

Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
Interventions: monoclonal antibody SGN-30, placebo, vinorelbine tartrate, pegylated liposomal doxorubicin hydrochloride, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study; Biological · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Pertuzumab, Placebo, Trastuzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 4,804 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 114
States / cities: Scottsdale, Arizona • Everett, California • Greenbrae, California + 92 more

Conditions: Breast Cancer
Interventions: Bevacizumab 7.5 and TAC, Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), Bevacizumab 15 and TAC, Placebo 15 and TAC; Drug
Lead sponsor: Translational Oncology Research International; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 5
States / cities: Los Angeles, California • Pomona, California • Orlando, Florida + 2 more

Conditions: Soft Tissue Sarcoma
Interventions: Doxorubicin, APX005M; Drug
Lead sponsor: Alexander Z. Wei, MD; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Duarte, California • St Louis, Missouri • New York, New York

Conditions: Breast Adenocarcinoma
Interventions: Bevacizumab, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Quality-of-Life Assessment; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 4,994 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 840
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 548 more

Conditions: Gastric Cancer
Interventions: Rilotumumab, Placebo, Epirubicin, Cisplatin, Capecitabine; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 16
States / cities: Tucson, Arizona • Aurora, Colorado • Pueblo, Colorado + 13 more

Conditions: Triple Negative Breast Cancer
Interventions: Placebo, Atezolizumab; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Enrollment: 1,550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 212
States / cities: Mobile, Alabama • Anchorage, Alaska • Jonesboro, Arkansas + 164 more

Conditions: Triple-negative Breast Cancer
Interventions: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Placebo, Nab-paclitaxel, Doxorubicin, Cyclophosphamide, Filgrastim, Pegfilgrastim; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 12
States / cities: Palo Alto, California • Norwalk, Connecticut • Carrollton, Georgia + 8 more

Conditions: Large B-cell Lymphoma
Interventions: Golcadomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 46
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 38 more

Conditions: Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Interventions: Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Doxorubicin-Eluting Beads, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Mitomycin, Pharmacological Study, Placebo Administration, Sorafenib Tosylate; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 281
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 183 more

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Tafasitamab, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 47
States / cities: Daphne, Alabama • Anaheim, California • Clovis, California + 44 more

Conditions: Lymphoma
Interventions: Bendamustine, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, PCI-32765 (Ibrutinib), Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 32
States / cities: Gilbert, Arizona • Campbell, California • Duarte, California + 29 more

Conditions: Lymphoma, Non-Hodgkin
Interventions: Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 10
States / cities: Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more

Search by objective public record fields.

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)

APX005M and Doxorubicin in Advanced Sarcoma

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)